KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Gains from Investment Securities (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Gains from Investment Securities data on record, last reported at $1.4 million in Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 7.39% year-over-year to $1.4 million; the TTM value through Sep 2025 reached $1.4 million, down 7.39%, while the annual FY2025 figure was $1.2 million, 268.58% up from the prior year.
  • Gains from Investment Securities reached $1.4 million in Q3 2025 per RIGL's latest filing, up from $1.4 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $13.1 million in Q3 2023 and bottomed at -$510000.0 in Q1 2022.
  • Average Gains from Investment Securities over 5 years is $2.8 million, with a median of $1.0 million recorded in 2022.
  • Peak YoY movement for Gains from Investment Securities: plummeted 8400.0% in 2022, then surged 141366.9% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $39000.0 in 2021, then soared by 1669.23% to $690000.0 in 2022, then soared by 394.44% to $3.4 million in 2023, then crashed by 55.44% to $1.5 million in 2024, then decreased by 7.39% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $1.4 million in Q3 2025, $1.4 million in Q2 2025, and $605514.0 in Q1 2025.